# Praxis Precision Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/praxis-precision-medicines

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.praxismedicines.com
- Total disclosed funding: $167M
- Latest round: Series C (Jul 28, 2020)
- Investors on record: 15

## About

Founded in 2015 by co-founders David Goldstein, Kiran Reddy, and Steven Petrou and based in Massachusetts, US, Praxis Precision Medicines, Inc. researches and develops therapies for neurological disorders. The company utilizes genome sequencing to determine parts of the brain that light up with regard to diseases such as epilepsy, mood disorders, pain syndromes, and movement disorders. In March 2024, Praxis Precision Medicines, Inc. raised USD 187.5 million in a private placement, selling 3.31 million shares at USD 56.5 apiece on the Nasdaq Global Select Market. In addition, underwriters were granted a 30-day option to purchase up to 530,973 additional shares.


The company product pipeline includes several drug candidates in different stages of clinical trials, including PRAX-944 for essential tremor and PRAX-628 for specific types of epilepsy. The cerebrum platform utilizes genetic insights to identify potential drug targets for CNS disorders characterized by imbalances in neuronal excitation and inhibition. Additionally, the solidus platform utilizes antisense oligonucleotide (ASO) technology to regulate the expression of genes linked to CNS disorders.

## Funding rounds

- Series C, Jul 28, 2020, $110M — Blackstone Group, Novo Holdings, Adage Capital Management, Qatar Investment Authority, Verition Fund Management, Cormorant Asset Management, Avoro Capital Advisors, Point72, Eventide Asset Management, OCV Partners, Vida Ventures, Surveyor Capital, Irving Investors, Ample Plus Fund Partnership LTD
- Series C, Nov 17, 2019, $57M — Novo Holdings, Clarus Ventures, Eventide Asset Management, Vida Ventures

## Investors

- Novo Holdings — Series C
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series C
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series C
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series C
- Blackstone Group (https://capitalatlas.ai/funds/blackstone-group) — Series C
- Adage Capital Management — Series C
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series C
- Verition Fund Management — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Avoro Capital Advisors — Series C
- Point72 (https://capitalatlas.ai/funds/point72) — Series C
- OCV Partners (https://capitalatlas.ai/funds/ocv-partners) — Series C
- Surveyor Capital — Series C
- Irving Investors (https://capitalatlas.ai/funds/irving-investors) — Series C
- Ample Plus Fund Partnership LTD — Series C